Incidence and prevalence rate estimation of GH treatment exposure in Piedmont pediatric population in the years 2002-2004: Data from the GH registry

Journal of Endocrinological Investigation

Volumn 29, Issue 5, 2006, Pages 438-442

  Migliaretti, Giuseppe ^a   Aimaretti, G ^b   Borraccino, A ^a   Bellone, J ^c   Vannelli, S ^a   Angeli, A ^a   Benso, L ^a   Bona, G ^d   Camanni, F ^b   de Sanctis, C ^c   Ravaglia, A ^e   Cavallo, F ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^d UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^e Pharmaceutical Division   (Italy)

Author keywords

Epidemiology; GH deficiency; Incidence; Prevalence

Indexed keywords

ARGININE; CLONIDINE; GLUCAGON; GONADORELIN; GROWTH HORMONE; LEVODOPA; PYRIDOSTIGMINE;

ADOLESCENT; ARTICLE; CALCULATION; CHILD; DRUG EXPOSURE; EPIDEMIOLOGICAL DATA; FACTUAL DATABASE; FEMALE; GROWTH HORMONE DEFICIENCY; HUMAN; HYPOPITUITARISM; INCIDENCE; ITALY; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRADER WILLI SYNDROME; PREVALENCE; PUBLIC HEALTH SERVICE; REGIONALIZATION; REGISTER; TURNER SYNDROME;

EID: 33745889002     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03344127     Document Type: Article

References (18)

1. GH Research Society. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the growth hormone research society workshop on adult growth hormone deficiency. J Clin Endocrinol Metab 1998, 83: 379-81.
2. GH Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH research society. J Clin Endocrinol Metab 2000, 85: 3990-3.
3. Erfurth EM, Bengtsson BA, Christiansen JS, Bulow B, Hagmar L. Premature mortality and hypopituitarism. Lancet 2001, 357: 1972-4.
4. Bulow B, Hagmar L, Orbaek P, Osterberg K, Erfurth EM. High incidence of mental disorders, reduced mental well-being and cognitive function in hypopituitary women with GH deficiency treated for pituitary disease. Clin Endocrinol (Oxf) 2002, 56: 183-93.
5. Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997, 46: 75-81.
6. Wyatt D. Lessons from the national cooperative growth study. Eur J Endocrinol 2004, 151 (Suppl 1): S55-9.
7. Guyda HJ. Four decades of growth hormone therapy for short children: what have we achieved? J Clin Endocrinol Metab 2005, 84: 4307-16.
8. Ranke MB, Wilton P. Growth hormone therapy in KIGS-10 years' experience. Barth Verlag Heidelberg Leipzig 1999, 10-20.
9. Parkin JM. Incidence of growth hormone deficiency. Arch Dis Child 1974, 49: 904-5.
10. Lindsay R, Feldkamp M, Harris D, Robertson J, Rallison M. Utah Growth Study: growth standards and the prevalence of growth hormone deficiency. J Pediatr 1994, 125: 29-35.
11. Thomas M, Massa G, Craen M, et al. Prevalence and demographic features of childhood growth hormone deficiency in Belgium during the period 1986-2001. Eur J Endocrinol 2004, 151: 67-72.
12. Regal M, Paramo C, Sierra SM, Garcia-Mayor RV. Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol (Oxf) 2001, 55: 735-40.
13. Coste J, Letrait M, Carel JC, et al. Long-term results of growth hormone treatment in France in children of short stature: population, register based study. BMJ 1997, 315: 708-13.
14. Gazzetta Ufficiale n. 7 del 10 gennaio 2001 - Ministero della Sanith.
15. Altman DG, Machin D, Bryant T, Gardner MJ. Statistics with confidence. Bristol: BMJ Books. 2000.
16. La Banca Dati Demografica Evolutiva della Regione Piemonte: http://www.regione.piemonte.it/stat/bdde/index.htm
17. Supplemento ordinario alla "Gazzetta Ufficiale" no 259 del 4 novembre 2004 - Ministero della Sanità; Note AIFA 2004 (Revisione Note CUF).
18. NOTE AIFA - http://www.simg.it/news/farmaco/note/Note_Aifa_2004.pdf